Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties - PubMed (original) (raw)
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties
S P Arneric et al. Alzheimer Dis Assoc Disord. 1995.
Abstract
Compounds that activate neuronal nicotinic acetylcholine receptors (nAChRs) may have potential benefit in the treatment of dementia, especially Alzheimer disease (AD). This article summarizes the preclinical pharmacology of ABT-418 [(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole], a novel analog of (-)-nicotine that is being clinically evaluated for the treatment of AD. ABT-418 is a cholinergic channel activator (ChCA) with cognitive enhancement and anxiolytic-like activity possessing a substantially reduced side-effect profile compared to (-)-nicotine [Arneric SP, Sullivan JP, Briggs CA, et al. (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl)Isoxazole (ABT-418): A novel cholinergic ligand with cognition enhancing and anxiolytic activity. I. In vitro activity. J Pharmacol Exp Ther 1994 ;270:310-318; Decker MW, Brioni JD, Sullivan JP, et al. (S)-3-Methyl-5-( 1-Methyl-2-Pyrrolidinyl)Isoxazole (ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 1994a;270:319-328; Decker MW, Curzon P, B rioni JD, Arne ric SP. Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. Eur J Pharmacol 1994;261:217-222; Garvey DS, Wasicak JT, Decker MW, et al. Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J Med Chem 1994;37:1055-1059]. ABT-418 may be the first agonist of nAChRs to be developed and evaluated specifically for the treatment of AD. Some brief speculation will be given on the potential benefits that this or other ChCAs may have in treating neurodegenerative disorders as compared with (-)-nicotine, and how this differs from other potential treatment approaches.
Similar articles
- (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT, et al. Decker MW, et al. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28. J Pharmacol Exp Ther. 1994. PMID: 7913497 - (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS, et al. Arneric SP, et al. J Pharmacol Exp Ther. 1994 Jul;270(1):310-8. J Pharmacol Exp Ther. 1994. PMID: 7518514 - Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist.
Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD, Martin BR. Damaj MI, et al. Psychopharmacology (Berl). 1995 Aug;120(4):483-90. doi: 10.1007/BF02245822. Psychopharmacology (Berl). 1995. PMID: 8539331 - Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.
Sullivan JP, Decker MW, Donnelly-Roberts D, Brioni JD, Bannon AW, Holladay MW, Anderson DJ, Briggs CA, Williams M, Arneric SP. Sullivan JP, et al. Proc West Pharmacol Soc. 1995;38:127-30. Proc West Pharmacol Soc. 1995. PMID: 7480004 Review. - ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.
Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP. Rueter LE, et al. CNS Drug Rev. 2004 Summer;10(2):167-82. doi: 10.1111/j.1527-3458.2004.tb00011.x. CNS Drug Rev. 2004. PMID: 15179445 Free PMC article. Review.
Cited by
- Analgesic potential of transdermal nicotine patch in surgery: a systematic review and meta-analysis of randomised placebo-controlled trials.
da Silva Barbirato D, de Melo Vasconcelos AF, Dantas de Moraes SL, Pellizzer EP, do Egito Vasconcelos BC. da Silva Barbirato D, et al. Eur J Clin Pharmacol. 2023 May;79(5):589-607. doi: 10.1007/s00228-023-03475-7. Epub 2023 Mar 22. Eur J Clin Pharmacol. 2023. PMID: 36947193 Review. - Progress in the development of new drugs in Alzheimer's disease.
Piau A, Nourhashémi F, Hein C, Caillaud C, Vellas B. Piau A, et al. J Nutr Health Aging. 2011 Jan;15(1):45-57. doi: 10.1007/s12603-011-0012-x. J Nutr Health Aging. 2011. PMID: 21267520 - Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
Wilens TE, Decker MW. Wilens TE, et al. Biochem Pharmacol. 2007 Oct 15;74(8):1212-23. doi: 10.1016/j.bcp.2007.07.002. Epub 2007 Jul 7. Biochem Pharmacol. 2007. PMID: 17689498 Free PMC article. Review. - Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model.
Kalra R, Singh SP, Pena-Philippides JC, Langley RJ, Razani-Boroujerdi S, Sopori ML. Kalra R, et al. Clin Diagn Lab Immunol. 2004 May;11(3):563-8. doi: 10.1128/CDLI.11.3.563-568.2004. Clin Diagn Lab Immunol. 2004. PMID: 15138183 Free PMC article. - Nicotine self-administration impairs hippocampal plasticity.
Abrous DN, Adriani W, Montaron MF, Aurousseau C, Rougon G, Le Moal M, Piazza PV. Abrous DN, et al. J Neurosci. 2002 May 1;22(9):3656-62. doi: 10.1523/JNEUROSCI.22-09-03656.2002. J Neurosci. 2002. PMID: 11978841 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical